Table 1. Characteristics of 5 RCTs.
| GOG218 | ICON7 | OCEANS | AURELIA | GOG213 | |
|---|---|---|---|---|---|
| Primary endpoint | PFS | PFS | PFS | PFS | OS |
| Patients enrolled | Stage III (incompletely resectable) or stage IV | Stage I-III or StageIV or Inoperable Stage III | Platinum-sensitive recurrent ovarian cancer (recurrence ≥6 months after completing platinum-based therapy) | Platinum-resistant recurrent ovarian cancer that had progressed ≤6 month after completing platinum-based therapy | Platinum-sensitive recurrent ovarian cancer |
| GOC/ECOG PS | GOG PS 0-2 | ECOG PS 0-2 | ECOG PS 0-1 | ECOG PS 0-2 | GOG PS 0-2 |
| Sample size | 1248 | 1528 | 484 | 361 | 748 |
| Average age (year) |
60 | 57 | 61 | 61 | 60 |
| Histology | Epithelial ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer | Epithelial ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer | Epithelial ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer | Epithelial ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer | Epithelial ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer |
| Control arm | Cycles 1–6: C (AUC 6) + P (175 mg/m2)+ PL, q3w Cycles 7–22: PL, q3w |
Cycles 1–6: C (AUC 5 or 6)+ P (175 mg/m2), q3w | Cycles 1–10: G (1,000 mg/m2 on days 1 and 8) + C (AUC 4 on day 1) + PL (15 mg/kg on day 1), q3w | Cycles 1-PD: PAC (80 mg/m2 days 1, 8, 15, and 22 q4w); or TOP (4 mg/m2, days 1, 8, 15 q4w or 1.25 mg/m2, days 1–5 q3w); or PLD (40 mg/m2 day 1 q4w) | Paclitaxel (175 mg/m2) + Carboplatin (AUC5) |
| Experimental arm | Cycles 1–6: C (AUC 6) + P (175 mg/m2) + Bev (15 mg/kg), q3w Cycles 7–22: Bev (15 mg/kg), q3w |
Cycles 1–6: C (AUC 5 or 6)+ P (175 mg/m2)+ Bev (15 mg/kg), q3w Cycles 7–18: Bev (15 mg/kg), q3w |
Cycles 1–10: G (1,000 mg/m2 on days 1 and 8) + C (AUC 4 on day 1) + Bev (15 mg/kg on day 1), q3w | Cycles 1-PD: Chemotherapy + Bev (15 mg/kg q3w or 10 mg/kg), q2w |
Bev (15 mg/kg) + P (175 mg/m2) + C (AUC5), followed by Bev maintenance |
PFS, progression-free survival; OS, overall survival; GOG, Gynaecological Oncology Group; ECOG, Eastern Cooperative Oncology Group; PS, performance status; C, carboplatin; AUC, area under curve; P, paclitaxel; Bev, bevacizumab; PL, Placebo; G, gemcitabine; PAC, weekly paclitaxel; TOP, topotecan; PLD, pegylated liposomal doxorubicin; PD, progressive disease.